Oncology
Categories
Early Phase / Multiple Disease Site 32
Precision Medicine 1
Preventative, Supportive Care, and Wellness 1
Brain and Spine Cancers 6
Breast 10
Cell Therapy Protocols 9
Endocrine Cancers
Eye/Orbital Cancers
GI Cancers 20
Gynecologic Cancers 15
Prostate and Urologic Cancers 23
Head and Neck 14
Hematologic / Blood Related Cancers 49
Sarcoma 7
Skin 5
Thoracic and Chest Cancers 20
Protocols
ALLIANCE-MM1MDS-A01 Phase II OPEN TO ACCRUAL
A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study
ECOG-EA4232 Phase III OPEN TO ACCRUAL
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
ECOG-EA7222 Phase III OPEN TO ACCRUAL
A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
IIT-AKHTAR-CILTA-TALQ Phase I OPEN TO ACCRUAL
A Phase Ib Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma
INCYTE-INCA035784-101 Phase I OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms
INCYTE-INCA-34176-254 Phase II OPEN TO ACCRUAL
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination with Ruxolitinib in Participants with Newly Diagnosed Chronic Graft-Versus-Host Disease
LILLY-J2N-MC-JZNY Phase IV OPEN TO ACCRUAL
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
MERCK-MK2140-011-00 Phase II OPEN TO ACCRUAL
A Randomized, Open-Label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-Naïve Participants with GCB Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)
MODERNA-MRNA-2808-P101 Phase I/II OPEN TO ACCRUAL
A Phase 1 2, Open-Label, Multicenter Study of mRNA-2808 in Participants with Relapsed or Refractory Multiple Myeloma
NEOGENE-NT-112-301 Phase I OPEN TO ACCRUAL
An Open-Label, Phase 1, Multi-Center Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation
NEOGENE-NT-175-201 Phase I OPEN TO ACCRUAL
An Open-Label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation
STEMLINE-MEN2312-01 Phase I OPEN TO ACCRUAL
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
SWOG-MM1OA-S03 Phase II OPEN TO ACCRUAL
A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy
SWOG-MM1YA-S01 Phase II OPEN TO ACCRUAL
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial
TERREMOTO-TER-2013-C01 Phase I/II OPEN TO ACCRUAL
A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations